Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaclyn LoPiccolo

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivoJoell J Gills, Jaclyn Lopiccolo, Junji Tsurutani, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Rare germline structural variants increase risk for pediatric solid tumorsRiaz Gillani, Ryan L Collins, Jett Crowdis, et al.
JTO Clinical and Research Reports|September 21, 2023
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional StudyLeou Ismael Banla, Alice Tzeng, John P Baillieul, et al.
Science (New York, N.Y.)|January 2, 2025
Rare germline structural variants increase risk for pediatric solid tumorsRiaz Gillani, Ryan L Collins, Jett Crowdis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 13, 2025
High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer ConsortiumYanhong Liu, Yafang Li, Jinyoung Byun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivoJoell J Gills, Jaclyn Lopiccolo, Junji Tsurutani, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Rare germline structural variants increase risk for pediatric solid tumorsRiaz Gillani, Ryan L Collins, Jett Crowdis, et al.
JTO Clinical and Research Reports|September 21, 2023
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional StudyLeou Ismael Banla, Alice Tzeng, John P Baillieul, et al.
Science (New York, N.Y.)|January 2, 2025
Rare germline structural variants increase risk for pediatric solid tumorsRiaz Gillani, Ryan L Collins, Jett Crowdis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 13, 2025
High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer ConsortiumYanhong Liu, Yafang Li, Jinyoung Byun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Pageof 4